Earlier diagnoses and advancements in treatment options are providing hope for patients with endometrial cancer like Yaca.

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with ...

Kansas City, Kansas, residents are suing Harcros Chemicals, accusing the company of poisoning the air for decades with a ...

Researchers at McMaster University, Cleveland Clinic and Case Comprehensive Cancer Center have uncovered how a protein long ...

-- AstraZeneca is in talks with Summit Therapeutics for a deal in which it could pay as much as $15 billion over time to license a lung-cancer drug, Bloomberg reported Thursday, citing people familiar ...

Serious conditions behind bloody cough symptoms revealed. Life-threatening diseases that cause alarming blood in cough ...

The approval of sunvozertinib, an oral irreversible EGFR inhibitor, was supported by data from the WU-KONG1B trial (ClinicalTrials.gov Identifier: NCT03974022 ). The primary efficacy population ...

AstraZeneca PLC (AZN) and Summit Therapeutics Inc (SMMT) are reportedly discussing a $15 billion partnership to license the ...

An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable ...

The FDA has granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( ...

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...